Clinical Trials
7
Active:0
Completed:0
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Early Phase 1
1 (14.3%)Gene Therapy(FT-003) for Wet AMD
Phase 1
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06492863
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for DME
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06492876
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
Phase 1
Recruiting
- Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT06492850
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Gene Therapy for Diabetic Macular Edema
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05916391
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Early Phase 1
Recruiting
- Conditions
- X-Linked Retinitis Pigmentosa
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05874310
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Eye & ENT hospital of Fudan university, Shanghai, Shanghai, China
- Prev
- 1
- 2
- Next
News
No news found